AVRO VS SPRO Stock Comparison

Performance

AVRO
100/100

AVRO returned 78.43% in the last 12 months. Based on SPY's performance of -12.98%, its performance is above average giving it a score of 100 of 100.

SPRO
10/100

SPRO returned -39.36% in the last 12 months. Based on SPY's performance of 13.09%, its performance is below average giving it a score of 10 of 100.

Analyst Price Targets

AVRO
88/100

4 analysts offer 12-month price targets for AVRO. Together, they have an average target of 0, the most optimistic target put AVRO at 0 within 12-months and the most pessimistic has AVRO at 0.

SPRO
81/100

4 analysts offer 12-month price targets for SPRO. Together, they have an average target of 0, the most optimistic target put SPRO at 0 within 12-months and the most pessimistic has SPRO at 0.

Technicals

AVRO
25/100

AVRO receives a 25 of 100 based on 14 indicators. 3 are bullish, 10 are bearish.

SPRO
50/100

SPRO receives a 50 of 100 based on 14 indicators. 6 are bullish, 6 are bearish.

Earnings

AVRO
10/100

AVRO has missed earnings 13 times in the last 20 quarters.

SPRO
21/100

SPRO has missed earnings 6 times in the last 20 quarters.

Profit

AVRO
10/100

Out of the last 20 quarters, AVRO has had 1 profitable quarters and has increased their profits year over year on 1 of them.

SPRO
13/100

Out of the last 20 quarters, SPRO has had 1 profitable quarters and has increased their profits year over year on 2 of them.

Volatility

AVRO
25/100

AVRO has had a lower than average amount of volatility over the last 12 months giving it a score of 25 of 100.

SPRO
49/100

SPRO has had a lower than average amount of volatility over the last 12 months giving it a score of 49 of 100.

All score calculations are broken down here to help you make more informed investing decisions

AVROBIO, Inc. Common Stock Summary

Nasdaq / AVRO

Healthcare

Biotechnology

AVROBIO, Inc., a clinical-stage gene therapy company, develops ex vivo lentiviral-based gene therapies to treat rare diseases following a single dose worldwide. Its gene therapies employ hematopoietic stem cells that are collected from patients and modified with a lentiviral vector to insert functional copies of the gene that is defective in the target disease. The company's product includes AVR-RD-01, a gene therapy for the treatment of Fabry disease. It is also developing AVR-RD-02, which is in phase 1/2 clinical trial for the treatment of type 1 Gaucher disease; AVR-RD-03, for the treatment of Pompe disease; AVR-RD-04 for the treatment of cystinosis; AVR-RD-05 for the treatment of Hunter syndrome; and AVR-RD-06 that is in preclinical stage for the treatment of Gaucher disease type 3. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

Spero Therapeutics, Inc. Common Stock Summary

Nasdaq / SPRO

Healthcare

Biotechnology

Spero Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. The company's product candidates include tebipenem pivoxil hydrobromide (HBr), an oral carbapenem-class antibiotic to treat complicated urinary tract infections, including pyelonephritis for adults; SPR206, a direct acting IV-administered agent to treat MDR Gram-negative bacterial infections in the hospital; and SPR720, an oral antibiotic for the treatment of non-tuberculous mycobacterial pulmonary disease. It has license agreement with Meiji Seika Pharma Co., Ltd. to support the development of tebipenem HBr; license agreement with Everest Medicines to develop, manufacture, and commercialize SPR206 in Greater China, South Korea, and Southeast Asian countries; collaboration agreement with Bill & Melinda Gates Medical Research Institute to develop SPR720 for the treatment of lung infections caused by Mycobacterium tuberculosis; and license agreement with Vertex Pharmaceuticals Incorporated for patents relating to SPR720, as well as SPR719, an active metabolite. The company was founded in 2013 and is headquartered in Cambridge, Massachusetts.

Power up your portfolio